Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Revenue (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Revenue for 10 consecutive years, with $207.3 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 25.89% to $207.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $673.0 million through Dec 2025, up 20.18% year-over-year, with the annual reading at $673.0 million for FY2025, 20.18% up from the prior year.
  • Revenue for Q4 2025 was $207.3 million at Ultragenyx Pharmaceutical, up from $159.9 million in the prior quarter.
  • The five-year high for Revenue was $207.3 million in Q4 2025, with the low at $79.9 million in Q1 2022.
  • Average Revenue over 5 years is $119.1 million, with a median of $105.8 million recorded in 2022.
  • The sharpest move saw Revenue soared 173.75% in 2021, then fell 19.58% in 2022.
  • Over 5 years, Revenue stood at $83.4 million in 2021, then rose by 23.93% to $103.3 million in 2022, then grew by 23.02% to $127.1 million in 2023, then rose by 29.5% to $164.6 million in 2024, then grew by 25.89% to $207.3 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $207.3 million, $159.9 million, and $166.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.